HIV-1 protease and substrate coevolution validates the substrate envelope as the substrate recognition pattern

Journal of Chemical Theory and Computation

Volumn 8, Issue 2, 2012, Pages 703-714

  Özen, Aysegül ^a   Haliloǧlu, Türkan ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BOGAZICI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857088597     PISSN: 15499618     EISSN: 15499626     Source Type: Journal    
DOI: 10.1021/ct200668a     Document Type: Article

References (43)

1. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity Proc. Natl. Acad. Sci. U.S.A. 1988, 85 (13) 4686-4690
2. Navia, M. A.; Fitzgerald, P. M.; McKeever, B. M.; Leu, C. T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 Nature 1989, 337 (6208) 615-620 (Pubitemid 19054290)
3. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schneider, J.; Kent, S. B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease Science 1989, 245 (4918) 616-621 (Pubitemid 19213338)
4. Flexner, C. HIV drug development: the next 25 years Nat. Rev. Drug Discovery 2007, 6 (12) 959-966 (Pubitemid 350201786)
5. Coffin, J. M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy Science 1995, 267 (5197) 483-489
6. Ji, J. P.; Loeb, L. A. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro Biochemistry 1992, 31 (4) 954-958
7. Bally, F.; Martinez, R.; Peters, S.; Sudre, P.; Telenti, A. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors AIDS Res. Hum. Retroviruses 2000, 16 (13) 1209-1213
8. Doyon, L.; Croteau, G.; Thibeault, D.; Poulin, F.; Pilote, L.; Lamarre, D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors J. Virol. 1996, 70 (6) 3763-3769 (Pubitemid 26161824)
9. Mammano, F.; Petit, C.; Clavel, F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients J. Virol. 1998, 72 (9) 7632-7637 (Pubitemid 28377901)
10. Feher, A.; Weber, I. T.; Bagossi, P.; Boross, P.; Mahalingam, B.; Louis, J. M.; Copeland, T. D.; Torshin, I. Y.; Harrison, R. W.; Tozser, J. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites Eur. J. Biochem. 2002, 269 (16) 4114-4120 (Pubitemid 34994906)
11. La Seta Catamancio, S.; De Pasquale, M. P.; Citterio, P.; Kurtagic, S.; Galli, M.; Rusconi, S. In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure J. Clin. Microbiol. 2001, 39 (3) 1124-1129 (Pubitemid 32209733)
12. Zhang, Y. M.; Imamichi, H.; Imamichi, T.; Lane, H. C.; Falloon, J.; Vasudevachari, M. B.; Salzman, N. P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites J. Virol. 1997, 71 (9) 6662-6670 (Pubitemid 27355324)
13. Kolli, M.; Lastere, S.; Schiffer, C. A. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate Virology 2006, 347 (2) 405-409
14. Pai, V. B.; Nahata, M. C. Nelfinavir mesylate: a protease inhibitor Ann. Pharmacother. 1999, 33 (3) 325-339 (Pubitemid 29157745)
15. Patick, A. K.; Duran, M.; Cao, Y.; Shugarts, D.; Keller, M. R.; Mazabel, E.; Knowles, M.; Chapman, S.; Kuritzkes, D. R.; Markowitz, M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir Antimicrob. Agents Chemother. 1998, 42 (10) 2637-2644 (Pubitemid 28462907)
16. Kolli, M.; Stawiski, E.; Chappey, C.; Schiffer, C. A. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance J. Virol. 2009, 83 (21) 11027-11042
17. Prabu-Jeyabalan, M.; Nalivaika, E. A.; King, N. M.; Schiffer, C. A. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease J. Virol. 2004, 78 (22) 12446-12454 (Pubitemid 39458763)
18. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C. A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes Structure 2002, 10 (3) 369-381 (Pubitemid 34230624)
19. King, N. M.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Schiffer, C. A. Combating susceptibility to drug resistance: lessons from HIV-1 protease Chem. Biol. 2004, 11 (10) 1333-1338 (Pubitemid 39351371)
20. Ozen, A.; Haliloglu, T.; Schiffer, C. A. Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope J. Mol. Biol. 2011, 410 (4) 726-744
21. Cote, H. C.; Brumme, Z. L.; Harrigan, P. R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir J. Virol. 2001, 75 (2) 589-594 (Pubitemid 32037261)
22. Pettit, S. C.; Sheng, N.; Tritch, R.; Erickson-Viitanen, S.; Swanstrom, R. The regulation of sequential processing of HIV-1 Gag by the viral protease Adv. Exp. Med. Biol. 1998, 436, 15-25 (Pubitemid 28201260)
23. Rhee, S. Y.; Gonzales, M. J.; Kantor, R.; Betts, B. J.; Ravela, J.; Shafer, R. W. Human immunodeficiency virus reverse transcriptase and protease sequence database Nucleic Acids Res. 2003, 31 (1) 298-303 (Pubitemid 36150389)
24. Shafer, R. W. Rationale and uses of a public HIV drug-resistance database J. Infect. Dis. 2006, 194 (Suppl 1) S51-58
25. HIV Databases; http://www.hiv.lanl.gov.
26. HIV-1, Human Protein Interaction Database; http://www.ncbi.nlm.nih.gov/ RefSeq/HIVInteractions/.
27. Khudyakov, Y. Coevolution and HBV drug resistance Antiviral Ther. 2010, 15 (3 Pt B) 505-515
28. Hu, W. Correlated mutations in the four influenza proteins essential for viral RNA synthesis, host adaptation, and virulence: NP, PA, PB1, and PB2 Nat. Sci. 2010, 2 (10) 1138-1147
29. Qureshi, S. A. Hepatitis C virus - biology, host evasion strategies, and promising new therapies on the horizon Med. Res. Rev. 2007, 27 (3) 353-373 (Pubitemid 46668938)
30. Lara, J.; Xia, G.; Purdy, M.; Khudyakov, Y. Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy J. Virol. 2011, 85 (7) 3649-3663
31. Romano, K. P.; Ali, A.; Royer, W. E.; Schiffer, C. A. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding Proc. Natl. Acad. Sci. U.S.A. 2010, 107 (49) 20986-20991
32. Sayer, J. M.; Liu, F.; Ishima, R.; Weber, I. T.; Louis, J. M. Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease J. Biol. Chem. 2008, 283 (19) 13459-13470
33. The PyMOL Molecular Graphics System, version 1.4; Schrodinger, LLC: New York, 2011.
34. Case, D. A.; Cheatham, T. E.; Darden, T. A.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Mertz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; C. Schafmeister; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. AMBER 8, University of California: San Francisco, CA, 2004.
35. Case, D. A.; Cheatham, T. E., III; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber biomolecular simulation programs J. Comput. Chem. 2005, 26 (16) 1668-1688 (Pubitemid 43076180)
36. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 1983, 79, 926-935
37. Berendsen, H. J. C.; Postma, J. P. M; Vangunsteren, W. F.; Dinola, A.; Haak, J. R. Molecular-Dynamics with Coupling to an External Bath J. Chem. Phys. 1984, 81 (8) 3684-3690
38. Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A Smooth Particle Mesh Ewald Method J. Chem. Phys. 1995, 103 (19) 8577-8593
39. Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical-Integration of Cartesian Equations of Motion of a System with Constraints-Molecular-Dynamics of N-Alkanes J. Comput. Phys. 1977, 23 (3) 327-341
40. Humphrey, W.; Dalke, A.; Schulten, K., VMD: visual molecular dynamics. J. Mol. Graphics 1996, 14 (1), 33-38, 27-38. (Pubitemid 26152973)
41. Miller, I.; Miller, M. Mathematical Expectation. In John E. Freund's Mathematical Statistics, 6th ed.; Heath, A.; Grant, J., Eds.; Prentice-Hall: Upper Saddle River, NJ, 1999; pp 158-160.
42. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 2003, 24 (16) 1999-2012
43. MATLAB, R2008b; The MathWorks, Inc.: Natick, MA, 2008.